drugset
drugset / Trial / NCT00474188

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188 ↗

Phase 2 Terminated 26 enrolled Celgene Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Timeline

Start
2007-05
Primary completion
2008-12
Completion
2008-12

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Dexamethasone Small molecule 40 mg Oral

Indications

diffuse large B-cell lymphoma